Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Celltrion clinical trials
The registry lists 84 studies whose lead sponsor is Celltrion or one of 2 companies grouped under it. 4 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 21, 2026.
Keep track of what changes. Save the Celltrion studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Celltrion.
- Celltrion77 studiesSame company
Something wrong?
- 4 studies →
- Celltrion HealthCare France3 studies →Acquired — became part of Celltrion, Dec 28, 2023 · source ↗
Something wrong?
Focus areas
Conditions Celltrion leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Studies
Recruiting first, then most recently updated. Showing 50 of 84. Browse all 84 →
- ROLL'YN-OMA: an Observational Study in Patients Treated by Omlyclo®, an Omalizumab BiosimilarRecruitingNCT07425639
Sponsor listed in the registry: Celltrion HealthCare France · First submitted after Celltrion HealthCare France became part of Celltrion
- Efficacy and Safety of Add-On Therapy With Empagliflozin in Patients With Type 2 Diabetes on a Background of Alogliptin and MetforminRecruitingNCT07093476Phase 3
- ROLL'YN-UST: an Observational Study in Patients Treated by Steqeyma®, an Ustekinumab BiosimilarRecruitingNCT06997055
Sponsor listed in the registry: Celltrion HealthCare France · First submitted after Celltrion HealthCare France became part of Celltrion
- A Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients With Relapsing-remitting Multiple SclerosisRecruitingNCT05906992Phase 3
- A Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination With Lenalidomide and Dexamethasone in Patients With Refractory or Relapsed Multiple MyelomaActive, not recruitingNCT06952478Phase 3
- Phase I Study to Evaluate the Pharmacokinetics and Safety After Co-administration of L03RD1 and L03RD2 or Administration of L03TD1 in Healthy VolunteersCompletedNCT07533539Phase 1
- A Study to Compare the Auto-injector and Pre-filled Syringe of CT-P52 in Healthy Male SubjectsCompletedNCT07367958Phase 1
- A Study to Compare Effects and Safety of CT-P51 and Keytruda in Patients With Previously Untreated Metastatic Lung CancerActive, not recruitingNCT06939595Phase 3
- Efficacy and Safety of Pioglitazone Combination Therapy in Type 2 Diabetes Patients on a Background of Empagliflozin With MetforminCompletedNCT06571591Phase 3
- Efficacy and Safety of Ezetimibe/Rosuvastatin and Amlodipine Patients With High Blood Pressure and High CholesterolCompletedNCT07564726Phase 3
Sponsor listed in the registry: Celltrion Pharm, Inc. · First submitted after Celltrion Pharm, Inc. became part of Celltrion
- A Phase 3 Study to Evaluate Efficacy & Safety of Subcutaneous CT-P13 in Patients With Moderate to Severe Active Rheumatoid ArthritisCompletedNCT06738719Phase 3
- To Compare the Pharmacokinetics, Safety, and Immunogenicity of Subcutaneous CT-P6 and Herceptin in Healthy Male Subjects (Trastuzumab)CompletedNCT06687928Phase 1
- A Study to Evaluate the Safety of Remsima® SC in the Treatment of RA, AS, PsA and PsActive, not recruitingNCT05866614
- A Study to Evaluate the Effect of add-on Pioglitazone or Dapagliflozin in Participants With Type 2 Diabetes Mellitus Inadequately Controlled by DPP-4 Inhibitor and Metformin TherapyCompletedNCT03499704Phase 4
Sponsor listed in the registry: Celltrion Pharm, Inc. · First submitted after Celltrion Pharm, Inc. became part of Celltrion
- A Study to Compare the Auto-injector and Pre-filled Syringe of CT-P43 in Healthy Male SubjectsCompletedNCT06951828Phase 1
- A Study to Compare Efficacy and Safety of CT-P55 and Cosentyx in Patients With Moderate to Severe PsoriasisActive, not recruitingNCT06630559Phase 3
- Study to Compare Pharmacokinetics and Safety of CT-P52 and US-licensed Taltz in Healthy SubjectsActive, not recruitingNCT07200986Phase 1
- Phase I Study to Evaluate the Pharmacokinetics and Safety After Co-administration of L03RD1 and L03RD2 or Administration of CT-L03 in Healthy VolunteersCompletedNCT07158346Phase 1
- A Bioequivalence Study of CT-L02 Compared to Co-administration (CTL0201 and CTL0202) in Healthy VolunteersCompletedNCT07128654Phase 1
- Study to Evaluate and Compare the Efficacy and Safety of AZM and AML Combined and Alone in Mild-to-moderate Essential Hypertensive SubjectsCompletedNCT05385770Phase 3
- To Compare Efficacy and Safety of CT-P39 and EU-approved Xolair in Patients With Chronic Spontaneous UrticariaCompletedNCT04426890Phase 3
- To Compare the Pharmacokinetics, Safety and Immunogenicity of CT-P55 and Cosentyx in Healthy SubjectsCompletedNCT07054970Phase 1
- To Compare Efficacy and Safety of CT-P16 and European Union-Approved Avastin as First-Line Treatment for Metastatic or Recurrent Non-Squamous Non-Small Cell Lung CancerCompletedNCT03676192Phase 3
- Demonstrate Efficacy and Safety of Metastatic Breast CancerCompletedNCT01084876Phase 3
- Evaluate Safety, Efficacy and PharmacokineticsCompletedNCT01084863Phase 1/2
- An Observational Study to Evaluate Safety and Efficacy of Remsima™ in Patients With Ankylosing SpondylitisTerminatedNCT02557308
- An Observational Study to Evaluate Safety and Efficacy of Remsima™ in Patients With RATerminatedNCT02557295
- A Study to Compare Efficacy and Safety of CT-P47 and RoActemra in Patients With Rheumatoid ArthritisCompletedNCT05489224Phase 3
- To Compare Pharmacokinetics, Efficacy, and Safety of CT-P17 With Humira in Patients With Moderate to Severe Chronic Plaque PsoriasisCompletedNCT05495568Phase 3
- A Phase 3 Study to Compare Between CT-P41 and US-licensed Prolia in Postmenopausal Women With OsteoporosisCompletedNCT04757376Phase 3
- Study to Compare Efficacy and Safety of CT-P42 in Comparison With Eylea in Patients With Diabetic Macular EdemaCompletedNCT04739306Phase 3
- A Study for PMS of AZL-M/CLD FDC in the Treatment of Participants With Essential HTN in South KoreaCompletedNCT04470830
Sponsor listed in the registry: Celltrion Pharm, Inc. · First submitted after Celltrion Pharm, Inc. became part of Celltrion
- A Study for PMS of AZL-M in the Treatment of Adult Participants With Essential Hypertension in South KoreaCompletedNCT04470817
Sponsor listed in the registry: Celltrion Pharm, Inc. · First submitted after Celltrion Pharm, Inc. became part of Celltrion
- CT-P13 (Infliximab) Subcutaneous Administration in Patients With Moderately to Severely Active Crohn's Disease (LIBERTY-CD)CompletedNCT03945019Phase 3
- CT-P13 (Infliximab) Subcutaneous Administration in Patients With Moderately to Severely Active Ulcerative Colitis (LIBERTY-UC)CompletedNCT04205643Phase 3
- Phase I Study to Compare the Pharmacokinetics, Pharmacodynamics, and Safety Between CT-P41 and US-licensed Prolia in Healthy Male SubjectsCompletedNCT06037395Phase 1
- A Bioequivalence Study of L04TD3 Compared to Administration of L04RD1 in Healthy VolunteersCompletedNCT05993806Phase 1
- A Study to Compare the Efficacy and Safety of CT-P43 to Stelara in Patients With Plaque PsoriasisCompletedNCT04673786Phase 3
- To Compare the PK and Safety of Omalizumab (CT-P39, EU-approved Xolair, and US-licensed Xolair) in Healthy SubjectsCompletedNCT04018313Phase 1
- Compare the Auto-injector and Pre-filled Syringe of CT-P47 in Healthy SubjectsStatus unknownNCT05617183Phase 1
- A Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CT-G20 in Subjects With Obstructive Hypertrophic CardiomyopathyTerminatedNCT04418297Phase 1
- A Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P47 in Patients With Active Rheumatoid ArthritisStatus unknownNCT05725434Phase 3
- A Bioequivalence Study of CT-L01 Compared to Co-administration (ALO 12.5 mg and MET XR 500 mg) in Healthy VolunteersCompletedNCT05363592Phase 1
- A Food Effect Study of CT-L01 After Oral Administration in Healthy VolunteersCompletedNCT05364164Phase 1
- A Bioequivalence Study of L04TD1 Compared to Administration of L04RD1 in Healthy VolunteersCompletedNCT05568121Phase 1
- A Bioequivalence Study of CT-L01 Compared to Co-administration (ALO 25 mg and MET XR 1,000 mg) in Healthy VolunteersCompletedNCT05363384Phase 1
- A Bioequivalence Study of L04TD2 Compared to Administration of L04RD1 in Healthy VolunteersCompletedNCT05581693Phase 1
- A Study to Evaluate the Efficacy and Safety of CT-P27 in Acute Uncomplicated Influenza A InfectionTerminatedNCT03511066Phase 2
- To Evaluate the Safety, Tolerability and Pharmacokinetics of CT-P63 in Healthy SubjectsCompletedNCT05017168Phase 1
- Efficacy and Safety Evaluating Study of CT-P6 in Her2 Positive Early Breast CancerCompletedNCT02162667Phase 3